1. Scrip
  2. >>Business

Zydus Cadila Explores Orphan Drug Indication For NASH Candidate

Expects 20-25 New Product Launches In FY21

 
• By Vibha Ravi

Cadila is exploring orphan indications for saroglitazar magnesium, in addition to the approaching Phase III NASH clinical trials for its lead NCE. Meanwhile, it counts on new product launches and biosimilars to take its FY21 growth story ahead.

SC1910_Liver-tissue-samples_1052884202_1200.jpg
Cadila Explores More Indications For Its NASH Candidate • Source: Shutterstock

Cadila Healthcare Ltd., part of the Zydus Cadila group, is exploring orphan indications for its lead new chemical entity (NCE) saroglitazar magnesium in a move to shorten time to market and possibly also benefit from the assistance and tax incentives for clinical trials associated with an orphan drug candidate.

On a 5 February call post the announcement of its third quarter fiscal year 2020 results, the novel PPARα/γ agonist came up several times in analyst’s questions and company officials...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback